「ac」の検索結果
132件：11～15件目を表示
-
General Announcement: May 9, 2024 Senju Pharmaceutical Co., Ltd. Senju announces initiation of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion S...
https://www.senju.co.jp/sites/default/files/content_news/2024-05/ENG_20240509.pdf -
ピマリシン点眼液5%「センジュ」
mannopyranosyloxy） -1, 3, 26-trihydroxy-12-methyl- 10-oxo-6, 11, 28-trioxatricyclo[22.3.1.05,7 ]octacosa- 8, 14, 16, 18, 20-pentaene-25-carboxylic acid 構造式： 分子式：C33H47NO13 分子量：665.73 性 状：ピマリシンは白色∼黄白色...
https://www.senju.co.jp/sites/default/files/product_other_file/2023-06/pimaricin-5_202307_C1.pdf -
General Announcement: September 3, 2024 Senju Pharmaceutical Co., Ltd. Acquisition of Marketing Approval for “ Mytear LUMIFY” Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr....
https://www.senju.co.jp/sites/default/files/content_news/2024-08/ENG_20240903.pdf -
July 16, 2024 General Announcement: Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Senju has successfully completed Phase III clinical trials in Japan for the novel Dry Eye Disease tr...
https://www.senju.co.jp/sites/default/files/content_news/2024-07/ENG_20240716_0.pdf -
General Announcement: September 3, 2024 Senju Pharmaceutical Co., Ltd. Acquisition of Marketing Approval for “ Mytear LUMIFY” Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr....
https://www.senju.co.jp/sites/default/files/content_news/2024-08/ENG_20240903_0.pdf